Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have changed the treatment landscape of several cancer types. However, data are lacking with regard to the clinical responsiveness of ICIs in patients with advanced non-small cell lung cancer (NSCLC) after standard first-line chemotherapy. Therefore, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Lupeng, Gao, Shan, Du, Sicheng, Sun, Shengjie, Liang, Yanjie, Sun, Zhuoya, Li, Tao, Jia, Guhe, Li, Ke, Sun, Xiaohui, Jiao, Shunchang, Zhao, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745307/
https://www.ncbi.nlm.nih.gov/pubmed/36523994
http://dx.doi.org/10.3389/fonc.2022.974227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745307/
https://www.ncbi.nlm.nih.gov/pubmed/36523994
http://dx.doi.org/10.3389/fonc.2022.974227

Ejemplares similares